---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-064762"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:17:14.981957+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024

## Summary
- Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.
- Median follow-up 5.6 months; grade ≥3 TRAEs in 14% of patients, no treatment-related deaths.
- Neoadjuvant HB-200 + chemo showed deep responses in 81% (17/21) of HPV16+ oropharyngeal cancer patients.
- HB-700 preclinical data induced KRAS mutation-specific T cell responses; Phase I planned for KRAS-mutated cancers.

## SEC filing metadata
- accession: 0001104659-24-064762
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465924064762/0001104659-24-064762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465924064762/tm2415416d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-064762
- JSON: https://secwatch.observer/filing/0001104659-24-064762.json
- Plain text: https://secwatch.observer/filing/0001104659-24-064762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.